Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

BHST vs PBM: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

PBM Captures Overall Composite Edge (63.9 BUY vs 58.2 HOLD), While BHST Leads 4–1 on Growth & Valuation Pillars

PBM Overall Winner 6-Pillar Tally: BHST 4 – 1 PBM (1 Tie) Matrix Metrics: BHST 3 – 5 PBM

As of Nov 20, 2026, Psyence Biomedical Ltd. Common Shares (PBM) captures the overall head-to-head institutional edge over BioHarvest Sciences Inc. (BHST) on higher Unified Composite conviction (63.9/100 BUY vs. 58.2/100 HOLD) after splitting the core matrix 5–3 (led by Profitability & Quality), while BHST wins 4–1 across the 6-pillar growth and valuation breakdown. BHST trades at $1.30 (N/M Forward P/E, -18.0% operating margin) versus PBM at $2.97 (N/M Forward P/E, 0.0% operating margin).

  • Growth vs. Quality Trade-Off: PBM earns the overall head-to-head edge with a stronger Unified Composite Score (63.9/100 BUY vs. BHST 58.2/100 HOLD) and 1.13β · 124% Vol risk profile, whereas BHST leads top-line expansion (+3.8% YoY revenue growth, N/M PEG, and 4 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: BHST is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 37.2); meanwhile PBM is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 41.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About BHST vs PBM
BHST NASDAQ
BioHarvest Sciences Inc. Common Stock
Pharmaceutical Preparations
$1.30
-1.52% 1D
Market Cap $29.9M
TTM Revenue $35M
Forward P/E N/M
Beta / 30D Vol 0.25β · 86% Vol
Unified Composite Score
58.2 / 100 HOLD
Tech 75.0 Fund 57.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -9.1%), weak momentum, RSI 37
RSI-14: 37.2 · SMA20: $1.55 · SMA50: $1.58
PBM NASDAQ Head-to-Head Winner
Psyence Biomedical Ltd. Common Shares
Pharmaceutical Preparations
$2.97
+3.85% 1D
Market Cap $12.0M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.13β · 124% Vol
Unified Composite Score
63.9 / 100 BUY
Tech 88.0 Fund 64.0 Flow 50.0 Mom 64.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -10.5%), weak momentum, RSI 41
RSI-14: 41.4 · SMA20: $3.08 · SMA50: $4.37

6-Pillar Scorecard Institutional Category Breakdown (BHST 4 – 1 PBM)

Columns: Metric · BHST · PBM
1. Valuation Multiples BHST
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue 0.7x N/M
2. Growth & Scale BHST
Revenue Growth (YoY) +3.8% +0.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $35M N/A
Market Cap $29.9M $12.0M
3. Profitability & Quality PBM
Gross Margin 59.0% N/A
Operating Margin -18.0% 0.0%
Net Profit Margin -31.2% 0.0%
Return on Equity (ROE) -142.5% -58.6%
4. Balance Sheet & Cash Flow BHST
Cash Generation (TTM) -$9.4M N/A
Cash Flow Margin -26.6% N/A
Net Cash / Leverage $5.1M Net Cash $7.39 Book/Sh · -58.6% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat BHST
OpEx & R&D Intensity 77.0% of Rev ($27M) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Packaged Foods Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: BHST (3) vs PBM (5)
Institutional Metric BHST PBM Criterion Row Edge
Market Capitalization
Scale
$29.9M $12.0M Larger Scale BHST
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+3.8% +0.0% Higher Growth BHST
Operating Margin (TTM)
Profitability
-18.0% 0.0% Higher Margin PBM
Net Profit Margin
Profitability
-31.2% 0.0% Higher Margin PBM
Return on Equity (ROE)
Capital Efficiency
-142.5% -58.6% Higher ROE PBM
52-Week Range Position
Momentum
6% ($1–$7) 14% ($1–$17) Stronger Trend PBM
Beta / 30D Volatility
Risk Regime
0.25β · 86% Vol 1.13β · 124% Vol Lower Realized Risk BHST
Unified Institutional Score
Composite Signal
58.2 / 100 (HOLD) 63.9 / 100 (BUY) Higher Composite PBM
Trailing 12M Revenue (USD)
Operating Scale
$35M N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
59.0% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 0.7x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$9.4M ($5.1M Net Cash) N/A ($7.39 Book/Sh · -58.6% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon BHST +5.29 pp
BHST: -22.62% · PBM: -27.91%
3M Horizon PBM +6.97 pp
BHST: -36.59% · PBM: -29.62%
6M Horizon PBM +38.76 pp
BHST: -66.32% · PBM: -27.56%
1Y Horizon PBM +85.85 pp
BHST: -79.4% · PBM: +6.45%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on BHST vs PBM. Trailing 12-month operating profitability (BHST -18.0% vs PBM 0.0%) and valuation multiples (BHST N/M vs PBM N/M Forward P/E) are benchmarked directly in Pillar 4 below.

BHST ADR TTM Benchmark FX-Normalized USD
TTM Revenue$35M
Gross Margin59.0%
Op. Margin-18.0%
ROE / Fwd P/E-142.5% · N/M
PBM ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-58.6% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
BHST UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact BHST Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
PBM UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact PBM Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
BHST Moat Profile Cyclical / Execution-Driven Positioning
Packaged Foods Operator
Competes within the Packaged Foods value chain with $29.9M market capitalization and -18.0% operating margin.
OpEx & R&D Reinvestment 77.0% of Rev ($27M)
90D Engineering Disclosures 0 Published
PBM Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $12.0M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ BHST vs PBM Key Questions & Quantitative Answers

As of Nov 20, 2026, Psyence Biomedical Ltd. Common Shares (PBM) captures the overall head-to-head institutional edge over BioHarvest Sciences Inc. (BHST) on higher Unified Composite conviction (63.9/100 BUY vs. 58.2/100 HOLD) after splitting the core matrix 5–3 (led by Profitability & Quality), while BHST wins 4–1 across the 6-pillar growth and valuation breakdown. BHST trades at $1.30 (N/M Forward P/E, -18.0% operating margin) versus PBM at $2.97 (N/M Forward P/E, 0.0% operating margin). Growth vs. Quality Trade-Off: PBM earns the overall head-to-head edge with a stronger Unified Composite Score (63.9/100 BUY vs. BHST 58.2/100 HOLD) and 1.13β · 124% Vol risk profile, whereas BHST leads top-line expansion (+3.8% YoY revenue growth, N/M PEG, and 4 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: BHST is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 37.2); meanwhile PBM is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 41.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

BHST leads the Growth & Scale pillar: BHST posts +3.8% YoY revenue growth and +0.0% YoY earnings growth on $35M TTM revenue (59.0% gross margin, -18.0% operating margin), compared with PBM at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, BHST generates $35M in USD-normalized revenue versus N/A for PBM. In operating R&D and SG&A reinvestment, BHST deploys 77.0% of Rev ($27M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for PBM.

BHST screens cheaper on headline valuation multiples. BHST trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 0.7x EV/Revenue (-26.6% FCF margin), whereas PBM trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against BHST (-142.5% ROE) versus PBM (-58.6% ROE) capital efficiency.

In options market volatility and institutional positioning, BHST carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.25β · 86% Vol realized risk). By comparison, PBM carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.13β · 124% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.